Illumina Ventures is an independently managed venture capital firm focused on early-stage life science startups. The company invests in innovative genomics and precision medicine companies, leveraging the expertise and global network of its strategic partner, Illumina, Inc., a leader in genomics technology.

Illumina Ventures

Protillion Biosciences is a Stanford University spinout commercializing disruptive technology for therapeutic antibody and binder discovery. We have developed an entirely novel, powerful and high-throughput protein display platform designed to revolutionize traditional approaches to the design and development of protein-based drugs.

ARCH Venture Partners

Protillion Biosciences

Excited and honored to see Protillion Biosciences featured in Illumina Ventures company spotlight! Dramatically shortening the therapeutic protein discovery timeline is an exciting and challenging goal, and it's a privilege to contribute to this mission.

#Protillion #InnovationInHealthcare #proteinengineering #antibodydiscovery

Protillion wishes you a very Happy & Pumpkiny Halloween season!

Protillion pumpkins (Protumpkins?) carved most excellently by Michael Gotrik Adriana Arneson David Heiner Jacob Gano Melania Strycharska Lydia Fulton
Artistic display: Adriana Arneson
Picture credit : Melania Strycharska

Protillion is excited to announce that we have moved our headquarters to a  newly built out, spacious facility in Carlsbad! After 4 years in our humble Burlingame home, we are thrilled to begin a new chapter with all of our employees together under the same beautiful roof.

We are excited to welcome Dirk Zajonc as the Head of Antibody Engineering to Protillion! Dirk brings a wealth of academic and industry experience towards antibody engineering and developing therapeutic antibody drug candidates. We greatly look forward to building out the antibody engineering side of our company! 
[Dirk is looking to hire exceptional candidates to his team - look for updates from him]

We are excited to continue growing our teams at Protillion! We have been recently joined by three outstanding, super talented folks: 

Melania Strycharska in Platform Development, 
Adriana Arneson in Bioinformatics, & 
Hwai-En Ho in Engineering
 
We look forward to building the next generation of antibody discovery and therapeutics platforms together!

Also, we are still hiring across a number of teams - visit protillion.com/careers and check us out!

We are excited to welcome Eric Allen to the Protillion fold. Eric is a veteran Bioinformatics and Software Development leader with 20+ years of experience at numerous companies including Illumina and Boundless Bio. Eric will lead the development of world-class scientific software that will power antibody discovery and optimization on our platform. Welcome Eric Allen!


#hiring #software #development #experience

Metric
Company Name	Illumina Ventures
Symbol
MSH ID	COM:ILLUMINAVENTURES
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology and Genomics
Country	US
Stage
Employee Count	14
Website	illuminaventures.com
LinkedIn	protillion
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ILLUMINAVENTURES

Illumina Ventures

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue